Does RIBOCICLIB Cause Tumour marker increased? 317 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 317 reports of Tumour marker increased have been filed in association with RIBOCICLIB (KISQALI). This represents 1.1% of all adverse event reports for RIBOCICLIB.
317
Reports of Tumour marker increased with RIBOCICLIB
1.1%
of all RIBOCICLIB reports
37
Deaths
61
Hospitalizations
How Dangerous Is Tumour marker increased From RIBOCICLIB?
Of the 317 reports, 37 (11.7%) resulted in death, 61 (19.2%) required hospitalization, and 13 (4.1%) were considered life-threatening.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIBOCICLIB. However, 317 reports have been filed with the FAERS database.
What Other Side Effects Does RIBOCICLIB Cause?
Neutropenia (3,585)
Nausea (3,404)
Fatigue (3,327)
Malignant neoplasm progression (2,468)
Death (2,452)
Vomiting (1,953)
Diarrhoea (1,830)
White blood cell count decreased (1,683)
Pain (1,637)
Metastases to bone (1,538)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
ANASTROZOLE (142)
Which RIBOCICLIB Alternatives Have Lower Tumour marker increased Risk?
RIBOCICLIB vs RIBOFLAVIN
RIBOCICLIB vs RIBOFLAVIN 5'-PHOSPHATE
RIBOCICLIB vs RIBOFLAVIN 5^-PHOSPHATE
RIBOCICLIB vs RIFABUTIN
RIBOCICLIB vs RIFAMPICIN